A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1578
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 Bone marrow findings in blast phase of polycythemia vera. ---
2018 Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry. ET, FCM, MF, MPN
2018 Essential thrombocythemia treatment algorithm 2018. ET
2018 Evaluation of vascular events in patients with myeloproliferative syndromes and mutations of either the januskinase-2 or calreticulin gene at the university hospital Krems from 2008 to 2015. CALR, ET, JAK2, MF, MPN
2018 Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms. CR, IFN-alpha, MPN
2018 Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera. HU, TEs
2018 Incidence and impact of atrial arrhythmias on thrombotic events in MPNs. AA, DOAC, ET, LDA, MPN, VKA
2018 Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. ET, HPCs, PMF
2018 MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. ET, MPN, PMF
10  2018 Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. ET, MPNs, PMF, WBC
11  2018 Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. AML, ET, HU, MF
12  2018 Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. AYA, ET, MF, MPNs
13  2018 Polycythemia vera treatment algorithm 2018. ---
14  2018 Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia. ET
15  2018 SOHO State-of-the-Art Update and Next Questions: MPN. advSM, CALR, ET, JAK, JAK-STAT, MF, MPN, PMF
16  2018 Successful therapy of Pyoderma gangrenosum with a JAK2 inhibitor. PG
17  2018 The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. ET, MPN-U, MPNs, PMF, WHO
18  2018 Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan. ET, OS
19  2017 A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. ET, MYSEC-PM, SMF
20  2017 A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. CALR, ET, PMF
21  2017 A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm. MPN
22  2017 A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. AEs, ET, ORR
23  2017 A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. CV, ECLAP, HU, PHL
24  2017 After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera. ---
25  2017 Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. ALOX5
26  2017 Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study. ---
27  2017 Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. BM, ET, MPNs, MVD, PMF
28  2017 Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera. DXA, ET, HR-pQCT
29  2017 Bumpy road to the diagnosis of polycythaemia vera. ---
30  2017 CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. ET, MPNs
31  2017 CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. ET, MPN, PMF
32  2017 Can pegylated interferon improve the outcome of polycythemia vera patients? HU, PEG-IFN
33  2017 Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms. Ang II, Ao, CML, CT-1, ET, MPNs, PMF, STAT
34  2017 Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study. CI, CKD, eGFR, MPNs
35  2017 Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms. EMPs, ET, MPs, Ph-MPN, PMF, PMPs, RMPs
36  2017 Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. ET, MPN, PMF
37  2017 Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms. ET
38  2017 Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms. BID, ET, MEA, MPN, OD, TOR
39  2017 Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera. DM
40  2017 Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. ET, MPNs, PMF
41  2017 Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. ET, MF, MPN, MPNs
42  2017 Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey. HU
43  2017 Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. ET, hs-CRP, MPNs, PTX3
44  2017 Emerging treatments for classical myeloproliferative neoplasms. MPN
45  2017 Experience with ruxolitinib in the treatment of polycythaemia vera. HC, Hct
46  2017 Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. AVWS, ET
47  2017 FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disorders. CMPD, ET, PMF
48  2017 Frequency of polycythemia in individuals with normal complete blood cell counts according to the new 2016 WHO classification of myeloid neoplasms. ---
49  2017 Genetic Risk Assessment in Myeloproliferative Neoplasms. ET, PMF
50  2017 Histomorphological responses after therapy with pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). BM, ET, MR
51  2017 Imaging features of myeloproliferative neoplasms. CML, ET, MPNs, PMF
52  2017 Inflammation and myeloproliferative neoplasms. ET, hs-CRP, MF, MPN, PTX-3
53  2017 Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review. CKD, CML, HCL, HCV, HUS, IFN, MS, TMA, TTP
54  2017 JAK2 inhibitors for myeloproliferative neoplasms: what is next? MF
55  2017 Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. MPNs
56  2017 Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. BAT, PRO
57  2017 Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ET, PMF
58  2017 Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm. BMAs, ET, JAK2, MF, MPNs
59  2017 Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. MF, MPNs, RUX
60  2017 MLF1IP promotes normal erythroid proliferation and is involved in the pathogenesis of polycythemia vera. MLF1-IP
61  2017 Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender. ET, PMF
62  2017 Monocytosis in polycythemia vera: Clinical and molecular correlates. CMML, MFFS, WHO
63  2017 Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. CMPNs, ET, PMF
64  2017 Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. ET, MF, MPN, RS, SMR
65  2017 NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. ET, MF, MPNs
66  2017 Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. ET, IPF, IRF, MF, MPNs
67  2017 Polycythemia causing posterior segment vascular occlusions. CRAO
68  2017 Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. AVWS, ET
69  2017 Polycythemia Vera Management and Challenges in the Community Health Setting. ---
70  2017 Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches. JAK2, MYSEC-PM, PPV-MF
71  2017 Prevalence of Physical Problems Detected by the Distress Thermometer and Problem List in Patients With Myeloproliferative Disorders. MPNs
72  2017 Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. ET, HSC, JAK2, MPNs, PMF, PN
73  2017 Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. BM, MFFS, MPN
74  2017 Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature. ET, MPNs, Ph, PMF
75  2017 Progression of primary myelofibrosis to polycythemia vera: A case report. PMF
76  2017 Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications. BM, CFC, EC, ET, PB, Ph- MPN, PMF
77  2017 Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches. JAK2
78  2017 pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms. ET, MPNs, PMF
79  2017 Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera. PH
80  2017 Quantitative Proteome Heterogeneity in Myeloproliferative Neoplasm Subtypes and Association with JAK2 Mutation Status. CALR, ET, MPN, PMF
81  2017 Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013. ET, MPNs, PMF
82  2017 Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. IWG-MRT
83  2017 Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry. EPO, ET, MPN
84  2017 Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. BAT
85  2017 Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome. BCS, MPNs
86  2017 Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial. BAT, CMR, ET, HC, PMR
87  2017 Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. ET, MPN
88  2017 Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. ET, MPN, TN
89  2017 TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms. ET, MPNs, PMF, SNPs
90  2017 The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation. MF
91  2017 The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium. CALR, ET, JAK2, MPL, MPN, PMF, STAT
92  2017 The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. CALR, DEX, GR, N-CALR, proEry
93  2017 The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). TSS-C
94  2017 The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. ET, MF, MPNs, QOL
95  2017 The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. ---
96  2017 The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes. ET, MGUS, MM, MPN
97  2017 The role of certain gene polymorphisms involved in the apoptotic pathways in polycythemia vera and essential thrombocytosis. ET
98  2017 The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. ET, MF, PMF
99  2017 Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. ET, MPN, PMF
100  2017 Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera. IFN, pegIFNa, TTP